These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32219999)

  • 1. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection.
    Otsuka H; Murakami Y; Uemura K; Kondo N; Nakagawa N; Okada K; Seo S; Takahashi S
    J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):421-428. PubMed ID: 32219999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 5. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Lupinacci RM; Goloudina A; Buhard O; Bachet JB; Maréchal R; Demetter P; Cros J; Bardier-Dupas A; Collura A; Cervera P; Scriva A; Dumont S; Hammel P; Sauvanet A; Louvet C; Delpéro JR; Paye F; Vaillant JC; André T; Closset J; Emile JF; Van Laethem JL; Jonchère V; Abd Alsamad I; Antoine M; Rodenas A; Fléjou JF; Dusetti N; Iovanna J; Duval A; Svrcek M
    Gastroenterology; 2018 Mar; 154(4):1061-1065. PubMed ID: 29158190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
    González I; Goyal B; Xia MD; Pai RK; Ma C
    Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
    Luchini C; Brosens LAA; Wood LD; Chatterjee D; Shin JI; Sciammarella C; Fiadone G; Malleo G; Salvia R; Kryklyva V; Piredda ML; Cheng L; Lawlor RT; Adsay V; Scarpa A
    Gut; 2021 Jan; 70(1):148-156. PubMed ID: 32350089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J; Ke G; Bi R; Wu X
    J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma.
    Ahmad-Nielsen SA; Bruun Nielsen MF; Mortensen MB; Detlefsen S
    Pathol Res Pract; 2020 Jun; 216(6):152985. PubMed ID: 32360245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Clinicopathological Characteristics of Stage I-III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins.
    Liang Y; Cai X; Zheng X; Yin H
    Onco Targets Ther; 2021; 14():2203-2212. PubMed ID: 33814918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
    Taïeb J; Sayah L; Heinrich K; Kunzmann V; Boileve A; Cirkel G; Lonardi S; Chibaudel B; Turpin A; Beller T; Hautefeuille V; Vivaldi C; Mazard T; Bauguion L; Niger M; Prager GW; Coutzac C; Benedikt Westphalen C; Auclin E; Pilla L
    Eur J Cancer; 2023 Jul; 188():90-97. PubMed ID: 37229836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
    Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
    Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A correlation study of mismatch repair immunohistochemical protein expression of pancreatic solid tumors in cytology cell blocks and matching surgical specimens.
    Teodosescu A; Chan I; Elder J; Wu M
    Diagn Cytopathol; 2021 Jun; 49(6):700-705. PubMed ID: 33615705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].
    Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y
    Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997
    [No Abstract]   [Full Text] [Related]  

  • 17. Diabetes mellitus impacts on expression of DNA mismatch repair protein PMS2 and tumor microenvironment in pancreatic ductal adenocarcinoma.
    Pan X; Mizukami H; Hara Y; Yamada T; Yamazaki K; Kudoh K; Takeuchi Y; Sasaki T; Kushibiki H; Igawa A; Hakamada K
    J Diabetes Investig; 2023 Jan; 14(1):132-144. PubMed ID: 36453157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma.
    Jiang B; Zhou L; Lu J; Wang Y; Liu C; Liang Z; Zhou W; You L; Guo J
    J Gastroenterol Hepatol; 2021 Feb; 36(2):507-515. PubMed ID: 32875609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology.
    Vivaldi C; Genovesi V; Ugolini C; Bernardini L; Casadei-Gardini A; Formica V; Salani F; Orsi G; Massa V; Cacciato-Insilla A; Caccese M; Cesario S; Andrikou K; Graziani J; Campani D; Vasile E; Fontanini G; Fornaro L; Masi G
    Oncology; 2024; 102(2):157-167. PubMed ID: 37699372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.